Tag: antibody design

Pharmaceutical giant Takeda is expanding its AI-driven drug discovery efforts by entering into a significant multi-year research collaboration with Nabla Bio. This partnership, potentially worth over $1 billion, will leverage Nabla Bio's proprietary generative AI platform, JAM, for the *de novo* design of antibodies and other protein therapeutics, aiming to accelerate the development of novel treatments for challenging diseases.